Background/Aims: Hemorrhagic cystitis (HC) is a serious complication after hematopoietic stem cell transplantation (HSCT). Stromal cells have been tested as therapy for HC. Decidua stromal cells (DSCs) protect the fetus from the mother's immune system. Methods: Eleven patients with HC of grades 3-4 were treated with DSCs after HSCT. The median age was 33 years (range 8-50), and the median dose of DSCs was 1.5 × 106/kg (range 0.7-2.5). The patients were given 1 dose (1-4). Results: In 5 patients, HC disappeared within 5 days after DSC infusion. Patients who received DSCs within 3 days after the start of HC had a duration of HC of 5 days and a shorter duration of pain than patients who were given DSCs later (p = 0.02). Three patients received DSCs prepared in albumin instead of AB-plasma and tended to have a shorter duration of pain (p = 0.07). There was no infusion toxicity. Adverse events were those often seen after HSCT. Nine of the 11 patients (82%) were alive 1 year after HSCT. Conclusions: Based on this pilot study, we started a randomized, placebo-controlled double-blind study using 2 doses of 1 × 106 DSCs/kg suspended in albumin for treatment of early HC.

Keywords:
Allogeneic stem cell transplantation, Hemorrhagic cystitis, Mesenchymal stromal cells, Placenta-derived decidua stromal cells
1.
Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, Goodell BW, Hickman RO, Lerner KG, Neiman PE, Sale GE, Sanders JE, Singer J, Stevens M, Storb R, Weiden PL: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511-533.
2.
Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, Blanche S, Fischer A; The European Group for Bone Marrow Transplantation: Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995;345:1398-1402.
3.
Ringden O: Immunotherapy by allogeneic stem cell transplantation. Adv Cancer Res 2007;97C:25-60.
4.
de Padua Silva L, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M: Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010;95:1183-1190.
5.
Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, Baltadakis I, Dalle JH, Koc Y, Toporski J, Styczynski J, Yesilipek MA, Heinz W, Caniglia M, Rascon J, Fauser AA, Michallet M, Lopez-Corral L, Neuburger S, Tridello G, Einsele H; European Group for Blood and Marrow Transportation: Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis 2009;49:233-240.
6.
Childs R, Sanchez C, Engler H, Preuss J, Rosenfeld S, Dunbar C, van Rhee F, Plante M, Phang S, Barrett AJ: High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant 1998;22:889-893.
7.
Giraud G, Priftakis P, Bogdanovic G, Remberger M, Dubrulle M, Hau A, Gutmark R, Mattson J, Svahn BM, Ringden O, Winiarski J, Ljungman P, Dalianis T: BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant 2008;41:737-742.
8.
Hassan Z, Remberger M, Svenberg P, Elbander M, Omazic B, Mattsson J, Conrad R, Svahn BM, Ahlgren A, Sairafi D, Aschan J, Le Blanc K, Barkholt L, Ringden O: Hemorrhagic cystitis: a retrospective single-center survey. Clin Transplant 2007;21:659-667.
9.
Ost L, Lonnqvist B, Eriksson L, Ljungman P, Ringden O: Hemorrhagic cystitis - a manifestation of graft versus host disease? Bone Marrow Transplant 1987;2:19-25.
10.
Potácová Z DT, Le Blanc K, Ringden O: Hemorrhagic cystitis; in Wingard JR, Gastineau DA, Leather HL, Snyder EL, Szczepiorkowski ZM (eds): Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians. Bethesda, AABB, 2015, pp 529-538.
11.
Chong KT, Hampson NB, Corman JM: Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology 2005;65:649-653.
12.
Palandri F, Bonifazi F, Rossi C, Falcioni S, Arpinati M, Giannini MB, Ansaloni F, Bandini G, Baccarani M: Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. Bone Marrow Transplant 2005;35:529-530.
13.
Garderet L, Bittencourt H, Sebe P, Kaliski A, Claisse JP, Esperou H, Ribaud P, Estrade V, Gluckman E, Gattegno B: Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. Transplantation 2000;70:1807-1811.
14.
Bernardo ME, Locatelli F, Fibbe WE: Mesenchymal stromal cells. Ann NY Acad Sci 2009;1176:101-117.
15.
English K, French A, Wood KJ: Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 2010;7:431-442.
16.
Ringden O, Le Blanc K: Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol 2011;24:65-72.
17.
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
18.
Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397.
19.
Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J, Henningsohn L, Le Blanc K: Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21:2271-2276.
20.
Kebriaei P: Mesenchymal stromal cells: The magic band-aid? Acta Haematol 2015;133:70-71.
21.
Wang Y, Chen F, Gu B, Chen G, Chang H, Wu D: Mesenchymal stromal cells as an adjuvant treatment for severe late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Acta Haematol 2015;133:72-77.
22.
Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, Antonenas V, Huang G, Gottlieb D, Bradstock K, Atkinson K: Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol 2009;144:571-579.
23.
In't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH: Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004;22:1338-1345.
24.
Erkers T, Nava S, Yosef J, Ringden O, Kaipe H: Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner. Stem Cells Dev 2013;22:2596-2605.
25.
Karlsson H, Erkers T, Nava S, Ruhm S, Westgren M, Ringden O: Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin Exp Immunol 2012;167:543-555.
26.
Moll G, Ignatowicz L, Catar R, Luecht C, Sadeghi B, Hamad O, Jungebluth P, Dragun D, Schmidtchen A, Ringden O: Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev 2015;24:2269-2279.
27.
Erkers T, Kaipe H, Nava S, Mollden P, Gustafsson B, Axelsson R, Ringden O: Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with 111Indium radiolabeling. Stem Cells Dev 2015;24:253-263.
28.
Ringden O, Erkers T, Nava S, Uzunel M, Iwarsson E, Conrad R, Westgren M, Mattsson J, Kaipe H: Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 2013;31:592-601.
29.
Ringden O, Solders M, Erkers T, Nava S, Mollden P, Hultcrantz M, Kaipe H, Mattsson J: Successful reversal of acute lung injury using placenta-derived decidual stromal cells. J Stem Cell Res Ther 2014;4:244.
30.
Droller MJ, Saral R, Santos G: Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology 1982;20:256-258.
31.
Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Mellander L, Ljungman P, Jacobsen N: Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation group. Blood 1999;93:2196-2201.
32.
Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P, Martola J, Albiin N, Wernerson A, Soderberg M, Remberger M, Thorne A, Ringden O: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003;31:253-261.
33.
Remberger M, Svahn BM, Mattsson J, Ringden O: Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004;78:122-127.
34.
Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73:1729-1734.
35.
Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P, Aschan J, Barkholt L, Ringden O: Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002;100:4317-4324.
36.
Storb R, Thomas ED: Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985;88:215-238.
37.
Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J: Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22:755-761.
38.
Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM: Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-414.
39.
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K: Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant 2006;37:1051-1059.
40.
Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B, Mattsson J, Sparrelid E, Winiarski J, Ringden O: Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998;66:1330-1334.
41.
Ringden O, Leblanc K: Pooled MSCs for treatment of severe hemorrhage. Bone Marrow Transplant 2011;46:1158-1160.
42.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental Committee of the European Group for Blood and Marrow Transportation: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586.
43.
Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ, Canadian Critical Care Trials G: Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012;7:e47559.
44.
Baygan A, Aronsson-Kurttila W, Moretti G, Tibert B, Dahllof G, Klingspor L, Gustafsson B, Khoein B, Moll G, Hausmann C, Svahn BM, Westgren M, Remberger M, Sadeghi B, Ringden O: Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis. Front Immunol 2017;8:795.
45.
Karlsson H, Samarasinghe S, Ball LM, Sundberg B, Lankester AC, Dazzi F, Uzunel M, Rao K, Veys P, Le Blanc K, Ringden O, Amrolia PJ: Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008;112:532-541.
46.
Sadeghi B, Heshmati Y, Khoein B, Kaipe H, Uzunel M, Walfridsson J, Ringden O: Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo. Cytotherapy 2015;17:1732-1745.
47.
Ringden O, Baygan A, Remberger M, Gustafsson B, Winiarski J, Khoein B, Klingspor L, Westgren M, Sadeghi B: Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl Med, submitted.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.